Af­ter tak­ing a hard look at the da­ta, No­var­tis punts Aduro’s STING drug — the lat­est in a long line of set­backs

Things keep get­ting worse at the be­lea­guered Aduro.

Stephen Isaacs

Ten months af­ter CEO Stephen Isaacs was forced to re­struc­ture and down­size the staff af­ter a se­ries of set­backs, No­var­tis is dump­ing Aduro’s lead sur­viv­ing drug af­ter con­clud­ing from the clin­i­cal da­ta that there was no rea­son to push for­ward.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER